1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,804 | 1,860 | 20:34 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:50 | Faron Pharmaceuticals: Composition of Faron Pharmaceutical's Shareholders' Nomination Board | 141 | ACCESS Newswire | TURKU, FINLAND / ACCESS Newswire / December 17, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers... ► Artikel lesen | |
| FARON PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Do | Faron secures €10 million in second tranche of convertible bonds | 2 | Investing.com | ||
| Do | Faron Pharmaceuticals: Faron Issues Second Tranche of Bonds With an Aggregated Principal Amount of Eur 10 Million Under its Convertible Bond Arrangement | 262 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / December 11, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON, "Faron" or the "Company")(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| Do | Faron sichert sich 10 Millionen Euro durch zweite Tranche von Wandelanleihen | 2 | Investing.com Deutsch | ||
| 08.12. | Faron Pharmaceuticals: Faron Presents Updated BEXMAB Data at ASH 2025: Deep and Durable Responses in HR-MDS with Favorable Safety Profile | 294 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the frontline... ► Artikel lesen | |
| 04.12. | Faron Pharmaceuticals Ltd: Holding(s) in Company | 217 | ACCESS Newswire | TURKU, FINLAND / ACCESS Newswire / December 4, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) | Company announcement | December 04, 2025 at 18:00:00 EETTR-1: Standard form for notification of major... ► Artikel lesen | |
| 02.12. | Faron Pharmaceuticals Ltd: Grant of Options | 178 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / December 2, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies... ► Artikel lesen | |
| 01.12. | Faron appoints former AstraZeneca Netherlands finance chief as CFO | 4 | Alliance News | ||
| 01.12. | Faron Pharmaceuticals Ltd: Appointment of CFO | 212 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / December 1, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON)(HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company, announces the appointment... ► Artikel lesen | |
| 27.11. | Faron Pharmaceuticals: Faron's Financial Calendar for 2026 | 257 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / November 27, 2025 / Faron Pharmaceuticals Ltd. (HEL:FARON)(LSE:FARN), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies,... ► Artikel lesen | |
| 24.11. | Faron to issue second €10 million tranche of convertible bonds | 2 | Investing.com | ||
| 24.11. | Faron Pharmaceuticals: Inside Information: Faron Intends to Issue Second Tranche of Bonds with an Aggregated Principal Amount of Eur 10 Million Under Its Convertible Bond Arrangement | 494 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / November 24, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN, First North: FARON, "Faron" or the "Company"), a clinical-stage biopharmaceutical company developing novel immunotherapies... ► Artikel lesen | |
| 24.11. | Faron kündigt zweite Wandelanleihen-Tranche über 10 Mio. Euro an | 3 | Investing.com Deutsch | ||
| 04.11. | Faron Pharmaceuticals: Faron Announces Two Bexmarilimab Abstracts Accepted At Ash 2025, Including An Oral Presentation On Treatment Efficacy | 468 | ACCESS Newswire | This acceptance marks the fifth major medical conference this year to feature bexmarilimab in an oral session, reinforcing the drug's unique mechanism in hematologic malignancies and potential to improve... ► Artikel lesen | |
| 03.11. | Faron Pharmaceuticals: Faron Hits Key Milestone With Bexmab Phase 2 Completion, Advances To Registrational Trial With Fda Alignment | 370 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / November 3, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Having achieved all primary endpoints and secured FDA alignment, Faron formally concludes enrolment of... ► Artikel lesen | |
| 21.10. | Faron Pharmaceuticals Ltd: Holding(s) in Company | 275 | ACCESS Newswire | TURKU, FINLAND / ACCESS Newswire / October 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)Faron Pharmaceuticals Ltd | Company announcement | October 21, 2025 at 16:10:00 EESTTR-1: Standard form... ► Artikel lesen | |
| 20.10. | Faron says new data reinforces promise of bone marrow cancer drug | 1 | Alliance News | ||
| 20.10. | Faron strengthens bexmarilimab potential with fresh trial data | 3 | Sharecast | ||
| 20.10. | Faron Pharmaceuticals: Updated BEXMAB Phase I/II Data Presented at ESMO 2025 Shows Further Improvement, Strengthening the Clinical Profile of Bexmarilimab in Treatment-Naïve HR-MDS Patients | 353 | ACCESS Newswire | TURKU, FI / ACCESS Newswire / October 20, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Updated BEXMAB Phase I/II Data presented at ESMO 2025 shows further improvement, strengthening the clinical... ► Artikel lesen | |
| 03.10. | Faron Pharmaceuticals registers 527,948 new shares | 1 | Investing.com |
1 2 3 4 Weiter >>
61 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,15 | -0,45 % | 60 Prozent Aufwärtspotenzial?: BioNTech: Diese Gamechanger sind noch nicht im Kurs eingepreist! | © Foto: Sebastian Gollnow/dpa Für Anleger von BioNTech gab es 2025 nicht viel zu feiern. Auf Jahressicht hat die Aktie rund 15 Prozent verloren. Dabei sind die großen Innovationen im Krebsbereich noch... ► Artikel lesen | |
| EVOTEC | 5,170 | -0,77 % | Evotec Aktie: Finaler Selloff? | Dass Evotecs langjähriger Ankeraktionär Novo Holdings aussteigen will, wie Bloomberg berichtet, hat die Biotech-Aktie gestern deutlich unter Druck gebracht. Intraday fiel das TecDAX-Papier auf ein neues... ► Artikel lesen | |
| BB BIOTECH | 48,400 | +0,31 % | Jade Biosciences secures $45 million in private placement from BB Biotech | ||
| MEDIGENE | 0,023 | -24,18 % | MEDIGENE AG stürzt ab - ich traue meinen Augen nicht! | ||
| QIAGEN | 38,480 | +1,29 % | QIAGEN NV steht still - für mich ist das kein Stillstand! | ||
| CUREVAC | 3,600 | -12,07 % | EILMELDUNG: Curevac unter Druck - Anleger verlieren die Nerven! | ||
| MODERNA | 26,020 | +2,28 % | Moderna, Inc.: Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference | CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30... ► Artikel lesen | |
| AMGEN | 278,50 | +0,16 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| EPIGENOMICS | 0,902 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,670 | +1,78 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| BIOGEN | 146,30 | +0,24 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| BIOFRONTERA | 2,460 | -7,17 % | BIOFRONTERA AG: Jetzt kippt das Gleichgewicht! | ||
| ILLUMINA | 111,74 | -0,20 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,200 | +1,26 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| NANOREPRO | 1,490 | -2,30 % | EQS-News: NanoRepro AG: Aufsichtsratsmitglied kündigt Amtsniederlegung an | EQS-News: NanoRepro AG
/ Schlagwort(e): Personalie
NanoRepro AG: Aufsichtsratsmitglied kündigt Amtsniederlegung an
10.12.2025 / 08:35 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen |
Das Unternehmen FARON PHARMACEUTICALS OY kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,00 % bei einem Aktienkurs von 1,826 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FARON PHARMACEUTICALS OY finden Sie auf Wallstreet Online.